AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or ...

Agios Pharmaceuticals shares surged after the FDA approved expanded use of its drug mitapivat for treating anemia in alpha- and beta-thalassemia patients.

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

PanARMENIAN.Net - The Armenian government has revised the list of medical conditions determining military fitness, amending a 2018 decision that defined when a citizen or servicemember is considered ...

As of Wednesday, December 24, Agios Pharmaceuticals, Inc.’s AGIO share price has surged by 16.31%, which has investors questioning if this is right time to sell.

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, ...

As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...